Boehringer Ingelheim presents phase III results demonstrating clinical equivalence of adalimumab biosimilar candidate to HUMIRA®

Boehringer Ingelheim starts clinical study on interchangeability between its adalimumab biosimilar candidate and HUMIRA®.....»»

Cyltezo®, adalimumab biosimilar from Boehringer Ingelheim, approved in Europe for the treatment of multiple chronic inflammatory diseases.....»»

Boehringer Ingelheim receives positive CHMP opinion for adalimumab biosimilar CYLTEZO®.....»»

Boehringer Ingelheim initiates Phase IIa study of compound acquired from Pharmaxis in debilitating liver disease NASH.....»»

Final Phase III Study Results Confirm Benefit of Praxbind® as Reversal Agent for Pradaxa® Patients in Emergency Situations.....»»

Lupin JV announces outcome of Phase III study for biosimilar, Etanercept.....»»

Lupin JV announces outcome of Phase III study for biosimilar, Etanercept.....»»

Glenmark Pharma presents preliminary biomarker data on GBR 1302.....»»

Glenmark Pharma announces results from phase 3 safety study evaluating Ryaltris.....»»

Key sub-analyses of RE-DUAL PCI™ showed large reductions in the incidence of bleeding complications if Pradaxa® (dabigatran etexilate) dual therapy was used instead of warfarin triple therapy.....»»

Takeda Presents Updated Results from Pivotal Phase 2 ALTA Trial of ALUNBRIG™ (brigatinib) in ALK-Positive Non-Small Cell Lung Cancer.....»»

Glenmark’s dermatitis molecule displays positive results in phase-2a trial.....»»

Takeda and Seattle Genetics Announce Positive Results from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma.....»»

Encouraging Phase II survival data for nintedanib in malignant pleural mesothelioma presented at ASCO 2017.....»»

Boehringer Ingelheim to invest €65 million in avian vaccines.....»»

Boehringer Ingelheim and Lilly Announce an Academic Collaboration with University of Oxford to Investigate the Effects of Empagliflozin in People with Chronic Kidney Disease.....»»

Biocon partner Mylan enters pact with Fujifilm to commercialise Humira biosimilar in Europe.....»»

HeartSciences Announces Publication of Clinical Study Results in the Journal of the American College of Cardiology (JACC).....»»

Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors.....»»

Favorable safety profile of Pradaxa® (dabigatran etexilate) confirmed in large prospective real-world analysis.....»»